MA33199B1 - Compositions de vaccin et procédés pour le traitement de la mucormycose et d'autres maladies fongiques - Google Patents

Compositions de vaccin et procédés pour le traitement de la mucormycose et d'autres maladies fongiques

Info

Publication number
MA33199B1
MA33199B1 MA34256A MA34256A MA33199B1 MA 33199 B1 MA33199 B1 MA 33199B1 MA 34256 A MA34256 A MA 34256A MA 34256 A MA34256 A MA 34256A MA 33199 B1 MA33199 B1 MA 33199B1
Authority
MA
Morocco
Prior art keywords
methods
vaccine compositions
mucormycosis
fungal diseases
compositions
Prior art date
Application number
MA34256A
Other languages
Arabic (ar)
English (en)
Inventor
Ashraf S Ibrahim
Brad J Spellberg
Yue Fu
John E Edwards
Original Assignee
Los Angeles Biomed Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomed Res Inst filed Critical Los Angeles Biomed Res Inst
Publication of MA33199B1 publication Critical patent/MA33199B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)

Abstract

La présente invention concerne des compositions thérapeutiques et des procédés pour traiter ou prévenir une maladie ou des affections fongiques comprenant la mucormycose. Les procédés thérapeutiques et les compositions de l'invention comprennent des compositions de vaccin ayant un polypeptide FTR ou un fragment antigénique du polypeptide; un vecteur comprenant une séquence nucléotidique qui est sensiblement complémentaire d'au moins 18 nucléotides contigus de séquence FTR; un antisens; un petit ARN interférant ou un anticorps inhibiteur de FTR. Les compositions de vaccin de l'invention peuvent comprendre en outre un adjuvant.
MA34256A 2009-03-19 2010-03-19 Compositions de vaccin et procédés pour le traitement de la mucormycose et d'autres maladies fongiques MA33199B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16161409P 2009-03-19 2009-03-19
PCT/US2010/000820 WO2010107500A1 (fr) 2009-03-19 2010-03-19 Compositions de vaccin et procédés pour le traitement de la mucormycose et d'autres maladies fongiques

Publications (1)

Publication Number Publication Date
MA33199B1 true MA33199B1 (fr) 2012-04-02

Family

ID=42739922

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34256A MA33199B1 (fr) 2009-03-19 2010-03-19 Compositions de vaccin et procédés pour le traitement de la mucormycose et d'autres maladies fongiques

Country Status (16)

Country Link
US (2) US20120093828A1 (fr)
EP (1) EP2408804A4 (fr)
JP (1) JP2012520878A (fr)
KR (1) KR20110139743A (fr)
CN (1) CN102639557A (fr)
AU (1) AU2010226320A1 (fr)
CA (1) CA2755273A1 (fr)
CL (1) CL2011002284A1 (fr)
IL (1) IL215093A0 (fr)
MA (1) MA33199B1 (fr)
MX (1) MX2011009735A (fr)
NZ (2) NZ614255A (fr)
RU (1) RU2011142173A (fr)
SG (1) SG174413A1 (fr)
TN (1) TN2011000459A1 (fr)
WO (1) WO2010107500A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1403092B1 (it) 2010-12-01 2013-10-04 Univ Degli Studi Modena E Reggio Emilia Metodo per la diagnosi e/o il monitoraggio della mucormicosi.
WO2013040517A2 (fr) * 2011-09-15 2013-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Immunothérapie et diagnostic de la mucormycose au moyen de coth
US20160017293A1 (en) * 2012-08-15 2016-01-21 Neostem Oncology, Llc Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same
CN106590685A (zh) * 2015-10-19 2017-04-26 粮华生物科技（北京）有限公司 重金属污染土壤的原位生物修复制剂和修复方法
US20210284742A1 (en) * 2018-06-29 2021-09-16 University Of Maryland, Baltimore Methods of treating or preventing mucormycosis
CN120026036B (zh) * 2025-02-20 2025-11-21 沈阳农业大学 金针菇铁离子渗透酶基因FvFTR1及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100380A (en) * 1991-10-28 2000-08-08 Cytran, Inc. Immunomodulating peptides and methods of use
PH31594A (en) 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
MY129541A (en) * 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
EP1223308B1 (fr) * 2000-12-16 2007-01-24 ALSTOM Technology Ltd Composante d'une turbomachine
WO2002053181A1 (fr) * 2001-01-04 2002-07-11 University Of Saskatchewan Vaccin contre l'infection par la bacterie escherichia coli enterohemorragique
US7363166B2 (en) * 2001-03-30 2008-04-22 Council Of Scientific & Industrial Research Computational method for the identification of candidate proteins useful as anti-infectives
US7914799B2 (en) * 2001-08-27 2011-03-29 Immunitor USA, Inc. Anti-fungal composition
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
ITMI20022447A1 (it) 2002-11-19 2004-05-20 Carlo Ghisalberti Uso di piridinoni nel trattamento della purpura capillare ed affezioni cutanee correlate.
MXPA05007156A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Formulacion farmaceuticas aerosolizable para terapia para infecciones fungicas.
US7226600B2 (en) * 2003-06-11 2007-06-05 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
JP5173194B2 (ja) * 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
US7550286B2 (en) * 2004-11-04 2009-06-23 E. I. Du Pont De Nemours And Company Docosahexaenoic acid producing strains of Yarrowia lipolytica
MX2008012252A (es) * 2006-03-24 2009-01-14 Basf Plant Science Gmbh Proteinas que se relacionan con la respuesta al estres abiotico y homologos.
TWI448285B (zh) * 2006-07-13 2014-08-11 Los Angeles Biomed Res Inst 用以治療白黴菌症（ｍｕｃｏｒｍｙｃｏｓｉｓ）及其他真菌類疾病之組合物及方法

Also Published As

Publication number Publication date
JP2012520878A (ja) 2012-09-10
CN102639557A (zh) 2012-08-15
KR20110139743A (ko) 2011-12-29
SG174413A1 (en) 2011-10-28
US8444985B2 (en) 2013-05-21
TN2011000459A1 (en) 2013-03-27
NZ614255A (en) 2015-03-27
RU2011142173A (ru) 2013-04-27
IL215093A0 (en) 2011-11-30
EP2408804A4 (fr) 2012-10-03
AU2010226320A1 (en) 2011-10-13
US20100285024A1 (en) 2010-11-11
CL2011002284A1 (es) 2012-09-14
WO2010107500A1 (fr) 2010-09-23
EP2408804A1 (fr) 2012-01-25
NZ595271A (en) 2013-08-30
CA2755273A1 (fr) 2010-09-23
MX2011009735A (es) 2011-10-19
US20120093828A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
JP2023072074A (ja) Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
MA33199B1 (fr) Compositions de vaccin et procédés pour le traitement de la mucormycose et d'autres maladies fongiques
JP6643981B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP2010516290A5 (fr)
CN113144178B (zh) 采用精氨酸酶i调节免疫系统的方法和组合物
US20140004156A1 (en) Biological inhibitors of ror1 capable of inducing cell death
TWI377212B (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
MXPA05011110A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
MA32621B1 (fr) Traitement de maladie auto-immune et inflammatoire
JP2010150280A5 (fr)
JP2011522842A (ja) パーキンソン病に関連する症状の治療のための化合物
RU2012107993A (ru) Полипептиды porhyromonas gingivalis
JP2018528763A (ja) バイオフィルムの除去のためのペプチドおよび抗体
RU2015102027A (ru) Проникающие в клетку пептиды и способы идентификации проникающих в клетку пептидов
JP2015522264A5 (fr)
JP2013501007A5 (fr)
JP2022166193A (ja) インターフェロンレベルを低下させるのに有用な化合物
MX2012004448A (es) Clones infecciosos de torque teno virus.
WO2010075891A1 (fr) Fibcd1 pour la prévention et le traitement de maladies
CZ303409B6 (cs) Zkrácený a mutovaný lidský chemokin
AU2016263534A1 (en) Treatment and detection of trypanosomes
WO2005107357A3 (fr) Composes analogues de peptides analgesiques derives du venin de serpents crotalus durissus terrificus, leurs applications, compositions et procedes destines a la preparation et a la purification de ces composes
JP2018024700A (ja) 少なくとも２種類の可変表面タンパク質（ｖｓｐ）を発現する変性原生動物、それを含むワクチン及び製造方法、用途及び使用方法
MA33668B1 (fr) Anticorps chimériques spécifiques pour cd151 et leur utilisation dans le traitement du cancer